Company intelligence / Profile preview

Regedent

Zurich, Zurich, Switzerlandregedent.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Regedent’s products—including hyaluronic acid gels and porcine bone grafts—are clinically proven for use in periodontal regeneration, peri‐implantitis treatment, and bone augmentation. The company invests heavily in clinical research and collaborates with international experts to validate its solutions[5].

Therapeutic areas: OtherInfectious Diseases
Modalities: Hyaluronic acid-based therapyBone graft (porcine bone substitute)Membrane-based regenerative products
Industry: Therapeutic Medical Devices

Drug pipeline

5 assets

Clean&Seal

Commercial

Indications: Periodontal disease, Peri-implantitis

4 more assets in the full pipeline.

Request access →

Partnerships

RLS Global (worldwide licensing of PERISOLV)

Beyond the preview

Go deeper on Regedent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regedent.

Explore the full profile